Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs
Gilead Sciences, Inc. stated on Tuesday that new results from its HIV and COVID-19 research and development programs will be presented at the 29th Conference on Retroviruses and Opportunistic Infections (virtualCROI 2022), which will take place from February 12-16. The findings demonstrate Gilead’s unwavering commitment to improving global health via scientific innovation by tackling some of the world’s most difficult infections. Gilead’s dedication to inclusive research makes it easier to find and create person-centered therapy alternatives that meet the changing requirements of a diverse group of people.
“The HIV and COVID-19 pandemics continue to challenge the global community, requiring unprecedented coordination and collaboration of scientists, industry, and community partners to accelerate antiviral research and development. At Gilead, we will keep applying our long-standing expertise in virology to bring forward person-centered innovation to help fulfill these urgent global needs. We are pleased to present our latest data at CROI 2022 from across our research and development programs, as we work to advance therapies to help different populations impacted by COVID-19 and HIV,”said Frank Duff, MD, Senior Vice President, Virology Therapeutic Area Head, Gilead Sciences.